"Nonalcoholic
Steatohepatitis Market (Pipeline analysis, drug class and Geography) Global
Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 -
2020", indicates that the global nonalcoholic steatohepatitis (NASH)
market would reach $1.6 billion by 2020 registering CAGR of 25.6% from 2014 to
2020. The high prevalence of Type II diabetes and obesity, which lead to NASH
and other non-alcoholic fatty liver diseases (NAFLD), would boost market
growth. North America's heightened focus on NASH research has resulted in it
accounting for nearly half of the global market. It is also the region with the
maximum occurrences of NASH and other non-alcoholic fatty liver diseases.
Europe ranks second in terms of the prevalence of NASH. The number of patients
living with the diabetes worldwide is expected to soar from 371 million in 2012
to 552 million by 2030. This suggests that by 2030, there will be 3 new cases
of diabetes every 10 seconds.
"The rampant growth of
diabetes and obesity has prompted pharmaceutical manufacturers to seek out
novel pharmaceutical solutions to tap promising potential in NASH," states publisher analyst. "Instrumental initiatives and increasing clinical
trials for the development of novel NASH therapeutics will steer its faster
commercialization," adds the analyst. Concerted efforts in research and
development from companies such as Genfit, Gilead Science, Novo Nordisk, Raptor
Pharmaceutical Corp. and Intercepts Pharmaceuticals would help them gain core
competencies in this market. Dainippon Sumitomo Pharma (DSP), a partner of
Intercept Pharmaceuticals, initiated a phase 2 clinical trial to test the
safety and efficacy of daily dose of Obeticholic Acid (OCA) in 200 adult NASH
patients. The trial is expected to be completed in the first half of 2016.
Thus, prevalence of diabetes and research and developments in the field of
fatty liver disease therapeutics would supplement market growth in the next six
years.
Publisher analysis suggests
that commercialization of NASH therapeutics and diagnostics in the market would
not only lower healthcare expenses of patients but would also increase its
(NASH therapeutics) share in the overall fatty liver disease therapeutics
market. Commercialization of GFT505 and OCA would give the NASH therapeutics
market a boost as these drugs are meant to specifically treat fatty liver
diseases. Additionally, the popularity of diagnostic biomarker technologies in
the diagnosis of liver diseases would also accelerate market growth. However,
presence of stringent regulatory guidelines and insufficient information
regarding the pathophysiology of NASH tissue is considered to restraint in
commercialization of potential drugs. The number of patients living with the
diabetes worldwide is expected to soar from 371 million in 2012 to 552 million
by 2030. This suggests that by 2030, there will be 3 new cases of diabetes
every 10 seconds. "The rampant growth of diabetes and obesity has prompted
pharmaceutical manufacturers to seek out novel pharmaceutical solutions to tap
promising potential in NASH," states publisher analyst.
"Instrumental initiatives and increasing clinical trials for the development of novel NASH therapeutics will steer its faster
commercialization," adds the analyst. Concerted efforts in research and
development from companies such as Genfit, Gilead Science, Novo Nordisk, Raptor
Pharmaceutical Corp. and Intercepts Pharmaceuticals would help them gain core
competencies in this market. Dainippon Sumitomo Pharma (DSP), a partner of
Intercept Pharmaceuticals, initiated a phase 2 clinical trial to test the
safety and efficacy of daily dose of Obeticholic Acid (OCA) in 200 adult NASH
patients. The trial is expected to be completed in the first half of 2016.
Thus, prevalence of diabetes and research and developments in the field of
fatty liver disease therapeutics would supplement market growth in the next six
years.
Publisher analysis suggests
that commercialization of NASH therapeutics and diagnostics in the market would
not only lower healthcare expenses of patients but would also increase its
(NASH therapeutics) share in the overall fatty liver disease therapeutics
market. Commercialization of GFT505 and OCA would give the NASH therapeutics
market a boost as these drugs are meant to specifically treat fatty liver
diseases. Additionally, the popularity of diagnostic biomarker technologies in
the diagnosis of liver diseases would also accelerate market growth. However,
presence of stringent regulatory guidelines and insufficient information
regarding the pathophysiology of NASH tissue is considered to restraint in
commercialization of potential drugs. In Europe, NASH is most prevalent in
Germany, Italy, Spain, France and the United Kingdom. Intercept
Pharmaceuticals, in collaboration with DSP, is developing obeticholic acid for
commercialization in the United States and European countries.
This drug is expected to
receive commercial approval by the end 2017. Developing economies, particularly
in the Asia-Pacific region, are the fastest growing markets for NASH
therapeutics and are expected to have a double digit growth rate during the
analysis period. The chief reason behind this growth is the high prevalence of
nonalcoholic fatty liver diseases in densely populated countries such as China,
Japan and Korea with prevalence rate of 12% to 24% per year. In western
industrialized countries, the prevalence rate is estimated to be approximately
20% to 40%.Most giant biopharmaceutical manufacturing companies are currently
attempting to develop novel therapeutics for the treatment of NASH. These
companies are adopting clinical trials and approval as key strategies in order
to gain competitive edge. Most of these companies operate from the United
States and are collaborating with private research and academic institutes to
conduct clinical trials. Key companies profiled in the report are: Genfit,
Gilead Science, Novo Nordisk, Intercepts Pharmaceuticals, Enzo Biochem, Inc.
and Raptor Pharmaceutical Corp.
For more information see - http://mrr.cm/Z7L
No comments:
Post a Comment
Note: only a member of this blog may post a comment.